Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

JCO Early Release, published online ahead of print May 14 2003
Journal of Clinical Oncology, 10.1200/JCO.2003.04.001

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnson, D. H.
Right arrow Articles by Arteaga, C. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, D. H.
Right arrow Articles by Arteaga, C. L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Gefitinib in Recurrent Non-Small-Cell Lung Cancer:An IDEAL Trial?

David H. Johnson and Carlos L. Arteaga

Division of Hematology & Oncology Vanderbilt-Ingram Comprehensive Cancer Center Vanderbilt University School of Medicine Nashville, TN


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
D. H. Johnson
Targeted therapies in combination with chemotherapy in non-small cell lung cancer.
Clin. Cancer Res., July 15, 2006; 12(14): 4451s - 4457s.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. Wasil and S. M. Lichtman
Clinical Pharmacology Issues Relevant to the Dosing and Toxicity of Chemotherapy Drugs in the Elderly
Oncologist, September 1, 2005; 10(8): 602 - 612.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Noberasco, T. De Pas, G. Curigliano, S. Manzoni, L. Dodaro, G. Pelosi, L. Spaggiari, and F. De Braud
Immunohistochemical Detection of HER1/HER2 Can Be Considered a Predictive Marker of Gefitinib Activity in Non-Small-Cell Lung Cancer?
J. Clin. Oncol., February 1, 2005; 23(4): 921 - 922.
[Full Text] [PDF]

Home page
 JCOHome page
M. Fukuoka
In Reply:
J. Clin. Oncol., February 1, 2005; 23(4): 922 - 922.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Park, B. B. Park, J. Y. Kim, S.-H. Lee, S. I. Lee, H. Y. Kim, J. H. Kim, S. H. Park, K.-E. Lee, J. O. Park, et al.
Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer
Clin. Cancer Res., July 1, 2004; 10(13): 4383 - 4388.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Haringhuizen, H. van Tinteren, H. F. R. Vaessen, P. Baas, and N. van Zandwijk
Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients
Ann. Onc., May 1, 2004; 15(5): 786 - 792.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. J. Langer, P. Stephenson, A. Thor, M. Vangel, and D. H. Johnson
Trastuzumab in the Treatment of Advanced Non-Small-Cell Lung Cancer: Is There a Role? Focus on Eastern Cooperative Oncology Group Study 2598
J. Clin. Oncol., April 1, 2004; 22(7): 1180 - 1187.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2003 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online